Sunshine Lake Pharma (HKG:6887) began trading at HK$57.50 on the Hong Kong bourse on Thursday, following its listing by introduction, after completing a merger with Yichang HEC Changjiang Pharmaceutical (HKG:1558).
The vertically integrated drugmaker's listing involved no fundraising.
A total of 112.7 million Sunshine Lake H-shares were admitted to trading on the main board, issued to HEC shareholders at a share exchange ratio of 0.263614 Sunshine Lake share for each HEC H-share cancelled.